The development of tumor resistance to HER2 inhibitors is a problem for which there are multiple possible mechanisms, including loss of HER2 expression and HER3 ligand-dependent HER2-HER3 interactions leading to evasion of apoptosis [61]. The gene discussed is ERBB2; the disease is neoplasm.